Theragnostic aspects and radioimmunotherapy in pediatric tumors

42Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

Abstract

The use of theragnostic radiopharmaceuticals in nuclear medicine has grown rapidly over the years to combine the diagnosis and therapy of tumors. In this review, we performed web-based and desktop literature research to investigate and explain the potential role of theragnostic imaging in pediatric oncology. We focused primarily on patients with aggressive malignancies such as neuroblastoma and brain tumors, to select patients with the highest chance of benefit from personalized therapy. Moreover, the most critical and groundbreaking applications of radioimmunotherapy in children’s oncology were examined in this peculiar context. Preliminary results showed the potential feasibility of theragnostic imaging and radioimmunotherapy in pediatric oncology. They revealed advantages in the management of the disease, thereby allowing an intra-personal approach and adding new weapons to conventional therapies.

Cite

CITATION STYLE

APA

Cimini, A., Ricci, M., Chiaravalloti, A., Filippi, L., & Schillaci, O. (2020, June 1). Theragnostic aspects and radioimmunotherapy in pediatric tumors. International Journal of Molecular Sciences. MDPI AG. https://doi.org/10.3390/ijms21113849

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free